KCNQ2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL774698	0.77	20/20
SCHEMBL749463	0.73	20/20
SCHEMBL367538	1.00	19/20
SCHEMBL694023	0.62	19/20
SCHEMBL321477	1.00	17/20
SCHEMBL265831	0.72	16/20
SCHEMBL401818	0.71	16/20
SCHEMBL203109	0.54	15/20
SCHEMBL751185	0.56	13/20
SCHEMBL9148	0.55	13/20
SCHEMBL774620	0.59	12/20
SCHEMBL535403	0.53	12/20
SCHEMBL401850	0.64	11/20
Flupirtine (SCHEMBL505322)	0.86	10/20
Flupirtine (SCHEMBL505880)	0.80	10/20
Flupirtine (SCHEMBL505354)	0.74	10/20
SCHEMBL403408	0.72	10/20
SCHEMBL403003	0.68	10/20
Flupirtine (SCHEMBL25009)	1.00	9/20
Flupirtine (SCHEMBL505535)	0.98	9/20

Clinical trials — most relevant to KCNQ2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long QT Syndrome Screening in Newborns	PHASE2	UNKNOWN
Study to Treat Major Depressive Disorder With a New Medication	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
N-of-1 in ATS and MEPPC	PHASE2	NOT_YET_RECRUITING
A Study of JMT203 in Patients With Cancer Cachexia	PHASE1/PHASE2	RECRUITING
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
JMT106 Injection in the Treatment of Advanced Solid Tumors	PHASE1	RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Prospective Identification of Long QT Syndrome in Fetal Life	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes	nan	RECRUITING
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Na+ Channel mRNA Regulation in Heart Failure	nan	COMPLETED
Long QT Syndrome-Population Genetics and Cardiac Studies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNQ2 binder may also engage these)

Protein	Name	Similarity
O88943	—	1.000	O88943 →
Q9Z351	—	1.000	Q9Z351 →
Q8K3F6	—	1.000	Q8K3F6 →
O88944	—	1.000	O88944 →
Q9JK97	—	1.000	Q9JK97 →
P58126	—	1.000	P58126 →
Q9JK96	—	1.000	Q9JK96 →
Q9TTJ7	—	1.000	Q9TTJ7 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	1.000	landscape →
KCNQ4	Potassium voltage-gated channel subfamily KQT member 4	1.000	landscape →
P97414	—	0.999	P97414 →
O97531	—	0.998	O97531 →
KCNQ3	Potassium voltage-gated channel subfamily KQT member 3	0.997	landscape →
Q9MYS6	—	0.997	Q9MYS6 →
Q9JK45	—	0.997	Q9JK45 →
O70344	—	0.996	O70344 →
Q9Z0N7	—	0.996	Q9Z0N7 →
KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	0.994	landscape →
A6H8H5	—	0.994	A6H8H5 →
Q63099	—	0.993	Q63099 →
Q9TUI4	—	0.993	Q9TUI4 →
Q60610	—	0.992	Q60610 →
Q76LL6	—	0.992	Q76LL6 →
Q4ZHA6	—	0.992	Q4ZHA6 →
Q9R1T9	—	0.992	Q9R1T9 →
Q03717	—	0.992	Q03717 →
Q76N89	—	0.992	Q76N89 →
P59808	—	0.992	P59808 →
KCNH3	Voltage-gated inwardly rectifying potassium channel KCNH3	0.991	landscape →
A2AHC3	—	0.991	A2AHC3 →